| RAL-eve Study: Raltegravir Substitution Study NCT00523237 Stanford University Resultados publicados | Completado | No aplica | oct 2007 |
| Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects NCT00529243 Kaiser Permanente Resultados publicados | Completado | Fase 3 | sept 2007 |
| A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients NCT00488059 Hoffmann-La Roche Resultados publicados | Finalizado anticipadamente | Fase 4 | jun 2007 |
| Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load NCT00454337 French National Agency for Research on AIDS and Viral Hepatitis | Completado | Fase 3 | may 2007 |
| Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses NCT00460382 French National Agency for Research on AIDS and Viral Hepatitis | Completado | Fase 2 | may 2007 |
| Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects. NCT00460746 Tibotec, Inc Resultados publicados | Completado | Fase 3 | may 2007 |
| ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression. NCT00461266 Hoffmann-La Roche | Retirado | Fase 4 | abr 2007 |
| Clinical Trial of CNS-targeted HAART (CIT2) NCT00624195 University of California, San Diego Resultados publicados | Completado | Fase 2, Fase 3 | mar 2007 |
| SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC NCT00440271 Boehringer Ingelheim Resultados publicados | Finalizado anticipadamente | Fase 3 | feb 2007 |
| Study of Valproic Acid to Treat HIV Infected Adults NCT00312546 University of North Carolina, Chapel Hill | Finalizado anticipadamente | Fase 1 | jun 2006 |
| BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection NCT00337701 Hoffmann-La Roche | Completado | Fase 4 | jun 2006 |
| Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130) NCT00302822 French National Agency for Research on AIDS and Viral Hepatitis | Completado | Fase 3 | abr 2006 |
| BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. NCT00326963 Hoffmann-La Roche Resultados publicados | Completado | Fase 4 | mar 2006 |
| Fuzeon Viral Decay Pilot Study NCT00334022 Canadian Immunodeficiency Research Collaborative | Completado | No aplica | feb 2006 |
| A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience NCT00487188 Hoffmann-La Roche Resultados publicados | Completado | Fase 4 | nov 2005 |
| Metabolic Effects of Enfuvirtide in Healthy Volunteers NCT00657761 Hospital Clinic of Barcelona | Completado | Fase 4 | sept 2005 |
| WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. NCT00233883 Hoffmann-La Roche | Completado | Fase 4 | ago 2005 |
| A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study NCT00128830 Tibotec Pharmaceuticals, Ireland Resultados publicados | Completado | Fase 2 | jun 2005 |
| Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration NCT00333736 Canadian Immunodeficiency Research Collaborative | Completado | Fase 2 | may 2005 |
| Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) NCT00120367 French National Agency for Research on AIDS and Viral Hepatitis | Completado | Fase 2 | abr 2005 |
| A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection NCT02569502 Hoffmann-La Roche | Completado | Fase 4 | abr 2005 |
| A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy NCT00344760 University of Maryland, Baltimore | Completado | Fase 4 | ene 2005 |
| Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection NCT02733419 Hoffmann-La Roche | Completado | Fase 3 | dic 2004 |
| A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1 NCT00100984 Hoffmann-La Roche | Finalizado anticipadamente | Fase 4 | 21 de julio de 2004 |
| A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients NCT00089492 Hoffmann-La Roche | Completado | Fase 2 | jul 2004 |
| QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection NCT00232908 Hoffmann-La Roche | Completado | Fase 4 | jun 2004 |
| A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection NCT02582983 Hoffmann-La Roche Resultados publicados | Completado | Fase 4 | feb 2004 |
| Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults NCT00051831 National Institute of Allergy and Infectious Diseases (NIAID) | Completado | No aplica | oct 2003 |
| Cohort Study for Patients Using Fuzeon (Enfuvirtide) NCT00216359 Institute for Interdisciplinary Infectiology | Estado desconocido | — | may 2003 |
| Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus NCT00102934 National Institute of Allergy and Infectious Diseases (NIAID) | Estado desconocido | No aplica | mar 2003 |
| HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) NCT00192660 Kirby Institute | Completado | Fase 4 | feb 2003 |
| Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection NCT00050856 National Institute of Allergy and Infectious Diseases (NIAID) | Completado | Fase 3 | nov 2002 |
| T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents NCT00022763 Hoffmann-La Roche Resultados publicados | Completado | Fase 2 | ago 2001 |
| HIV Maintenance Therapy With T-20 During HAART Interruption NCT00013884 National Institute of Allergy and Infectious Diseases (NIAID) | Completado | Fase 2 | mar 2001 |
| An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection NCT01902615 Hoffmann-La Roche | Completado | — | ene 2001 |
| Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance NCT00187551 University of California, San Francisco | Completado | Fase 4 | may 2000 |
| The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV NCT00004735 National Institute of Allergy and Infectious Diseases (NIAID) | Completado | No aplica | feb 2000 |
| A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults NCT00002239 Hoffmann-La Roche | Completado | Fase 2 | may 1999 |
| T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs NCT00008528 Hoffmann-La Roche | Completado | Fase 3 | — |
| Study of Enfuvirtide in HIV-Positive Subjects NCT00086710 Trimeris | Completado | Fase 1 | — |